Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-27. (Canceled).

28. (Previously Presented). The process of Claim 46, wherein step b of Claim 46 is carried out by:

a. preparing a gene construct comprising a nucleic acid sequence encoding the peptide selected in step a of claim 46 adjacent to either the N-terminus or the C-terminus of a nucleic acid sequence encoding an Fc domain; and

b. b.expressing the gene construct.

29. (Previously Presented). The process of Claim 28, wherein the gene construct is expressed in an E. coli cell.

30 – 39. (Canceled).

40. (Previously Presented). The process of Claim 46, wherein step a of Claim 46 is carried out by a process comprising:

a. preparing a gene construct comprising a nucleic acid sequence encoding a first selected peptide and a nucleic acid sequence encoding an Fc domain;

b. conducting a polymerase chain reaction using the gene construct and mutagenic primers, wherein

i) a first mutagenic primer comprises a nucleic acid sequence complementary to a sequence at or near the 5' end of a coding strand of the gene construct, and

ii) a second mutagenic primer comprises a nucleic acid sequence complementary to the 3' end of the noncoding strand of the gene construct.

41-45. (Canceled).

46. (Currently Amended). A process for preparing a pharmacologically active compound, which comprises:

(a) selecting from a peptide phage display library at least one peptide sequence that modulates the activity of AGP-3;

(b) preparing a compound incorporating at least one said selected peptide sequence, wherein the compound has ~~of~~ the formula

$$(X^1)_a\text{-}F^1\text{-}(X^2)_b$$

and multimers thereof, wherein:

F^1 is an Fc domain;

X^1 and X^2 are each independently selected from $-(L^1)_c\text{-}P^1$, $-(L^1)_c\text{-}P^1\text{-}(L^2)_d\text{-}P^2$, $-(L^1)_c\text{-}P^1\text{-}(L^2)_d\text{-}P^2\text{-}(L^3)_e\text{-}P^3$, and $-(L^1)_c\text{-}P^1\text{-}(L^2)_d\text{-}P^2\text{-}(L^3)_e\text{-}P^3\text{-}(L^4)_f\text{-}P^4$

P^1, P^2, P^3, and P^4 are each independently the selected peptide sequences;

L^1, L^2, L^3, and L^4 are each independently linkers; and

a, b, c, d, e, and f are each independently 0 or 1, provided that at least one of a and b is 1;

wherein "peptide" refers to molecules of 2 to 40 amino acids.

47. (Original). The process of Claim 46, wherein the compound prepared is of the formulae

$$X^1\text{-}F^1$$

or

$$F^1\text{-}X^2.$$

48. (Original). The process of Claim 46, wherein the compound prepared is of the formulae

$$F^1\text{-}(L^1)_c\text{-}P^1$$

or

$$F^1\text{-}(L^1)_c\text{-}P^1\text{-}(L^2)_d\text{-}P^2.$$

49. (Original). The process of Claim 46, wherein F^1 is an IgG Fc domain.

50. (Original). The process of Claim 46, wherein F^1 is an IgG1 Fc domain.

51. (Original). The process of Claim 46, wherein F^1 comprises the sequence of SEQ ID NO: 2.

Claims 52-62 (Canceled).

63. (Previously Presented). The process of Claim 46 wherein a is 1 and b is 0.

64. (Previously Presented). The process of Claim 46 wherein X^1 is $-(L^1)_c-P^1-(L^2)_d-P^2$.

65. (Previously Presented). The process of Claim 63 wherein X^1 is $-(L^1)_c-P^1-(L^2)_d-P^2$.

66. (Previously Presented). The process of Claim 65 wherein L^1 is $(Gly)_5$.

67. (Previously Presented). The process of Claim 65 wherein L^2 is $(Gly)_5$.

68. (Previously Presented). The process of Claim 66 wherein L^2 is $(Gly)_5$.

69. (Previously Presented). The process of Claim 46 wherein the library is a phage display library.

70. (Previously Presented). The process of Claim 65 wherein the library is a phage display library.

71. (Previously Presented). The process of Claim 68 wherein the library is a phage display library.

72.-79. (Canceled)